The Global Oligonucleotide CDMO Market was valued at USD 2.3 billion in 2025 and is estimated to grow at a CAGR of 21.1% to reach USD 15.7 billion by 2035.
Market growth is being fueled by the rapid expansion of oligonucleotide-based therapeutic pipelines, increasing reliance on outsourcing by pharmaceutical and biotechnology companies, continuous advancements in oligonucleotide synthesis and delivery technologies, and growing investments in GMP manufacturing infrastructure. As more oligonucleotide therapies advance through clinical development and receive regulatory approvals, demand for specialized contract development and manufacturing organizations continues to rise across both clinical and commercial production. The oligonucleotide CDMO market plays a critical role by providing integrated development, process optimization, analytical support, and GMP manufacturing services for synthetic nucleic acid medicines. Increasing commercialization of RNA-based therapeutics is further accelerating the need for large-scale manufacturing capacity, advanced analytical capabilities, and regulatory-compliant production facilities. The continued expansion of oligonucleotide drug development programs and growing outsourcing preferences among pharmaceutical manufacturers are expected to reinforce long-term demand for specialized CDMO services throughout the forecast period.
The contract manufacturing segment generated USD 1.2 billion in 2025. Segment growth is supported by the increasing number of late-stage clinical programs and commercially approved oligonucleotide therapies requiring large-scale GMP production. Pharmaceutical and biotechnology companies continue to outsource manufacturing activities to specialized CDMOs to gain access to advanced production technologies, regulatory-compliant manufacturing facilities, and scalable commercial capabilities while minimizing significant capital expenditures associated with in-house manufacturing expansion.
The antisense oligonucleotides (ASO) segment held 38.7% share in 2025. Its leading position is supported by the continued expansion of approved therapies and a strong pipeline of clinical-stage drug candidates targeting multiple disease areas. Growing investment in antisense oligonucleotide research, combined with increasing commercial manufacturing requirements, continues to strengthen demand for specialized development, analytical, and GMP manufacturing services across this segment.
North America Oligonucleotide CDMO Market accounted for 51.7% share in 2025, maintaining its position as the leading regional market. Regional growth is supported by a highly developed pharmaceutical and biotechnology industry, advanced manufacturing capabilities, a well-established regulatory environment, and a strong concentration of specialized contract development and manufacturing organizations. The United States continues to dominate regional revenue due to its extensive biotechnology ecosystem, expanding clinical development activities, and the presence of numerous pharmaceutical companies and dedicated oligonucleotide CDMO service providers.
Major companies operating in the global oligonucleotide CDMO market include Lonza Group, Thermo Fisher Scientific, WuXi AppTec, ST Pharm, Agilent Technologies, Kaneka Eurogentec, PolyPeptide Group, Eurofins Scientific, GenScript Biotech, CordenPharma, Ajinomoto Bio-Pharma Services, Axolabs, Hongene Biotech, BioSpring, CPC Scientific, Bachem Holding, Aurigene Pharmaceutical Services, Asymchem Laboratories (Tianjin), and TriLink BioTechnologies. Companies operating in the oligonucleotide CDMO market are strengthening their market position by expanding GMP manufacturing capacity, investing in advanced synthesis technologies, and enhancing end-to-end development capabilities to support growing customer requirements. Many organizations are increasing investments in research and process optimization to improve manufacturing efficiency, product quality, and scalability for clinical and commercial production. Strategic collaborations with pharmaceutical and biotechnology companies continue to play an important role in securing long-term manufacturing agreements and expanding project pipelines. Companies are also pursuing geographic expansion through new production facilities, capacity additions, and acquisitions to improve global service capabilities.
This product will be delivered within 2-4 business days.
Market growth is being fueled by the rapid expansion of oligonucleotide-based therapeutic pipelines, increasing reliance on outsourcing by pharmaceutical and biotechnology companies, continuous advancements in oligonucleotide synthesis and delivery technologies, and growing investments in GMP manufacturing infrastructure. As more oligonucleotide therapies advance through clinical development and receive regulatory approvals, demand for specialized contract development and manufacturing organizations continues to rise across both clinical and commercial production. The oligonucleotide CDMO market plays a critical role by providing integrated development, process optimization, analytical support, and GMP manufacturing services for synthetic nucleic acid medicines. Increasing commercialization of RNA-based therapeutics is further accelerating the need for large-scale manufacturing capacity, advanced analytical capabilities, and regulatory-compliant production facilities. The continued expansion of oligonucleotide drug development programs and growing outsourcing preferences among pharmaceutical manufacturers are expected to reinforce long-term demand for specialized CDMO services throughout the forecast period.
The contract manufacturing segment generated USD 1.2 billion in 2025. Segment growth is supported by the increasing number of late-stage clinical programs and commercially approved oligonucleotide therapies requiring large-scale GMP production. Pharmaceutical and biotechnology companies continue to outsource manufacturing activities to specialized CDMOs to gain access to advanced production technologies, regulatory-compliant manufacturing facilities, and scalable commercial capabilities while minimizing significant capital expenditures associated with in-house manufacturing expansion.
The antisense oligonucleotides (ASO) segment held 38.7% share in 2025. Its leading position is supported by the continued expansion of approved therapies and a strong pipeline of clinical-stage drug candidates targeting multiple disease areas. Growing investment in antisense oligonucleotide research, combined with increasing commercial manufacturing requirements, continues to strengthen demand for specialized development, analytical, and GMP manufacturing services across this segment.
North America Oligonucleotide CDMO Market accounted for 51.7% share in 2025, maintaining its position as the leading regional market. Regional growth is supported by a highly developed pharmaceutical and biotechnology industry, advanced manufacturing capabilities, a well-established regulatory environment, and a strong concentration of specialized contract development and manufacturing organizations. The United States continues to dominate regional revenue due to its extensive biotechnology ecosystem, expanding clinical development activities, and the presence of numerous pharmaceutical companies and dedicated oligonucleotide CDMO service providers.
Major companies operating in the global oligonucleotide CDMO market include Lonza Group, Thermo Fisher Scientific, WuXi AppTec, ST Pharm, Agilent Technologies, Kaneka Eurogentec, PolyPeptide Group, Eurofins Scientific, GenScript Biotech, CordenPharma, Ajinomoto Bio-Pharma Services, Axolabs, Hongene Biotech, BioSpring, CPC Scientific, Bachem Holding, Aurigene Pharmaceutical Services, Asymchem Laboratories (Tianjin), and TriLink BioTechnologies. Companies operating in the oligonucleotide CDMO market are strengthening their market position by expanding GMP manufacturing capacity, investing in advanced synthesis technologies, and enhancing end-to-end development capabilities to support growing customer requirements. Many organizations are increasing investments in research and process optimization to improve manufacturing efficiency, product quality, and scalability for clinical and commercial production. Strategic collaborations with pharmaceutical and biotechnology companies continue to play an important role in securing long-term manufacturing agreements and expanding project pipelines. Companies are also pursuing geographic expansion through new production facilities, capacity additions, and acquisitions to improve global service capabilities.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Services, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Molecule Type, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Application, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
- Agilent Technologies
- Ajinomoto Bio-Pharma Services
- Asymchem Laboratories (Tianjin)
- Aurigene Pharmaceutical Services
- Axolabs
- Bachem Holding
- BioSpring
- CordenPharma
- CPC Scientific
- Eurofins Scientific
- GenScript Biotech
- Hongene Biotech
- Kaneka Eurogentec
- Lonza Group
- PolyPeptide Group
- ST Pharm
- Thermo Fisher Scientific
- TriLink BioTechnologies
- WuXi AppTec
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 154 |
| Published | July 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 2.3 Billion |
| Forecasted Market Value ( USD | $ 15.7 Billion |
| Compound Annual Growth Rate | 21.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 19 |
